NASDAQ · LIEN
Chicago Atlantic BDC, Inc.
$9.13-$0.02 (-0.22%)
Chicago Atlantic BDC, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.99% below the high.
Loading market information…
NASDAQ · ZYNE · USD
Stock price, earnings
Quote as of Oct 10, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Zynerba Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Zynerba Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2021 | Mar 1, 2022 | -$0.22+18.52% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$9.13-$0.02 (-0.22%)
Chicago Atlantic BDC, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.99% below the high.
$0.10-$0.00 (-0.21%)
Zomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.15% below the high.
$1.27$0.00 (0.0%)
IGM Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.36% below the high.
$1.07-$0.01 (-0.93%)
Surface Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.17% below the high.
$1.29-$0.07 (-5.15%)
Akoya Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.28% below the high.
$0.76$0.00 (0.0%)
The Valens Company Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
$1.91-$0.02 (-1.04%)
DURECT Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.65% below the high.
$1.12-$0.08 (-6.67%)
MindWalk Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 62.54% below the high.
